President Alberto Fernandez I headed this afternoon in pink house The first meeting of An interministerial committee made up of the ministries of Health, Science, Technology, Innovation and Productive DevelopmentWhich aims to advance projects for the production of vaccines of national origin, in addition to contributing to the development of “more value-added” medicines and less reliance on imports.
The owners of health bags participated in the meeting, Carla Vizzotti; science, technology and innovation, Daniel Filmus; and productive development, Mathias Colvas.
The Secretary for International Economic Relations also attended. Cecilia Todesca; Head of R + D + i Agency, Fernando Pierano; ANLAP chief; Anna Lea Allemand, Undersecretary of Health for Systems Integration and Primary Care. Gaston Moran; and Undersecretary of the Ministry of Knowledge Economy, Maria Apolito.
During the meeting, the presidency stated: The head of state was able to get acquainted with the lines carried out by the commission, among which was the work on the production of the Argentine vaccine against the coronavirus COVID-19., which focuses on three factors focusing on scientific excellence, regulation of public procurement, expansion and production at the national level.
The baggage holders made it clear to the President of the Republic that To advance the clinical phase of the vaccine, inter-agency follow-up evaluations will be conducted to allocate resources and resolve institutional and regulatory requirements. of projects between the public and private sectors being implemented.
The interministerial schedule for research, development and production of vaccines, therapies, diagnostics and other health technologies seeks to create Strategic framework for building policies for research, development and production of new technologies that enhance diagnosticstreatment and control of COVID-19 in the country.
What is more, It aims to develop other health technologies in order to maximize resources and enhance inter-ministerial coordination Health, Productive Development, Science, Technology and Innovation.
RNA messenger vaccines, a scientific milestone
At the end of September a promising news Which represents a scientific milestone for the country: Argentina will manufacture messenger RNA technology vaccines against COVID-19.
At a meeting two months ago between the scientific authorities of the World Health Organization and the Pan American Health Organization, two Argentine biotech manufacturers Sinergium Biotech and mAbxience were chosen to be the first, together with Brazil’s FIOCRUZ, to produce vaccines against COVID-19 using RNA technology. Express mail outside the United States. Infobae At the time, he agreed to the details of this disclosure that would allow for increased production capacity and expanded access to vaccines in the Americas.
After a rigorous process, selection was made by an independent panel of experts, the Vaccine Product Development Advisory Committee (PDVAC).roduct Development of Vaccines Advisory Committee). In the case of the Latin American region, the two selected proposals will allow for the establishment of two development and production centers with the capacity to use this vaccine manufacturing technology (messenger RNA) against COVID-19: one in Argentina through mAbxience and Sinergium; The other is in the Federative Republic of Brazil. This technology could also serve as the basis for the production of other vaccines important to the health system.
The renowned Institute of Technology in Immunology Bio-Manguinhos, part of the Oswaldo Cruz Foundation (FIOCRUZ), was selected for its progress in developing an innovative mRNA vaccine against COVID-19.
“Pop culture advocate. Troublemaker. Friendly student. Proud problem solver.”